Progyny
PGNY | NASDAQ
$37.15
+$0.97 (+2.68%)
At close: Nov 16, 2026, 4:00 PM ET
$35.47
-$1.68 (-4.51%)
Pre-market:
Nov 17, 2026, 4:15 AM ET
Progyny Company Profile
Company profile explainedCompany Profile
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
Key Executives
| Name | Position |
|---|---|
| Peter Anevski | Chief Executive Officer & Director |
| Mark S. Livingston | Chief Financial Officer |
| Melissa Cummings | Chief Operating Officer |
| Risa Fisher | Chief Marketing Officer |
| Steven Leist | Chief Technology Officer |
| Allison Swartz | Executive Vice President, General Counsel & Secretary |
| Cassandra Pratt | Chief Human Resources Officer |
| David J. Schlanger | Executive Chairman |
| Geoffrey Clapp | Chief Product Officer |
| James Hart | Vice President of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 16, 2026 | 4 | Filing |
| Sep 28, 2026 | 4 | Filing |
| Sep 23, 2026 | 144 | Filing |
| Sep 21, 2026 | 4 | Filing |
| Sep 18, 2026 | 4/A | [Amend] Filing |
| Sep 14, 2026 | 4 | Filing |
| Sep 10, 2026 | 144 | Filing |
| Sep 08, 2026 | 4 | Filing |
| Sep 08, 2026 | 4 | Filing |
Progyny
| Country | United States |
| IPO Date | Oct 25, 2019 |
| Industry | Medical - Healthcare Plans |
| Sector | Healthcare |
| Employees | 846 |
| CEO | Pete Anevski |
Contact Details
1359 Broadway New York City,
New York 10018 United States
Stock Details
| Ticker Symbol | PGNY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001551306 |
| CUSIP Number | 74340E103 |
| ISIN Number | US74340E1038 |
| SIC Code | 8090 |
Recent News
- 15 hours ago / zacks.comProgyny (PGNY) Is Up 3.85% in One Week: What You Should Know
- 6 days ago / fool.comProgyny: 3 Key Takeaways for Long-Term Investors
- 12 days ago / marketbeat.comProgyny Q3 Earnings Call Highlights
- 12 days ago / seekingalpha.comProgyny, Inc. (PGNY) Q3 2026 Earnings Call Transcript
- 12 days ago / zacks.comProgyny (PGNY) Tops Q3 Earnings and Revenue Estimates
- 13 days ago / globenewswire.comProgyny, Inc. Announces Third Quarter 2026 Results
- 20 days ago / globenewswire.comNew Progyny Study Examines Persistent Racial and Ethnic Differences in Fertility Treatment Initiation Despite Access to Benefits
- 22 days ago / globenewswire.comNew Progyny Study Finds Significant Improvement in Menopause Symptoms Through Connected Care Model
- 27 days ago / globenewswire.comProgyny, Inc. Announces Details for Its Third Quarter 2026 Results Report
- 1 month ago / globenewswire.comProgyny to Present New Menopause Research at The Menopause Society 2026 Annual Meeting
Add to Watchlist
Select watchlists to add or remove PGNY